文献速递免疫规划卫生政策与健康促进

中国婴儿肺炎球菌疫苗接种的成本效果分析

Cost-effectiveness analysis of pneumococcal vaccination for infants in China.
PubMed 文献 · Vaccine · 2016-10-31

中国未将肺炎球菌结合疫苗(PCV)纳入扩大免疫规划(EPI)。结果显示三种疫苗相较不接种均具成本效果,PCV-13因总成本降低而增量成本效果比最低(11464美元/质量调整生命年),为优选策略。

要点

  • PCV-7、PCV-10和PCV-13接种项目相较不接种均具成本效果。
  • PCV-13的增量成本效果比最低(11464美元/质量调整生命年)。
  • 敏感性分析显示增量成本效果比对急性中耳炎效用值、PCV-13成本和肺炎及急性中耳炎发病率最敏感。

核心结论

  • 中国政府应采取措施将肺炎球菌结合疫苗纳入扩大免疫规划,以降低幼儿肺炎球菌疾病负担。
  • 虽然所有疫苗接种均具成本效果,但PCV-13可为医疗系统节省更多成本,是优选策略。

研究设计与样本

  • 模型参数来源于文献综述。

主要发现

  • PCV-7、PCV-10和PCV-13接种项目相较不接种均具成本效果。
  • PCV-13的增量成本效果比最低(11464美元/质量调整生命年 vs PCV-10的16664美元/质量调整生命年 vs PCV-7的18224美元/质量调整生命年),因其总成本降低。
  • 敏感性分析显示增量成本效果比对急性中耳炎效用值、PCV-13成本和肺炎及急性中耳炎发病率最敏感。

关键数值与推荐

  • PCV-13增量成本效果比为11464美元/质量调整生命年。
  • PCV-10增量成本效果比为16664美元/质量调整生命年。
  • PCV-7增量成本效果比为18224美元/质量调整生命年。

临床怎么用

  • 原文建议中国政府将肺炎球菌结合疫苗纳入扩大免疫规划,并认为PCV-13为优选策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although China has a high burden of pneumococcal disease among young children, the government does not administer publicly-funded pneumococcal conjugate vaccines (PCV) through its Expanded Program on Immunization (EPI). We evaluated the cost-effectiveness of publicly-funded PCV-7, PCV-10, and PCV-13 vaccination programs for infants in China. METHODS: Using a Markov model, we simulated a cohort of 16 million Chinese infants to estimate the impact of PCV-7, PCV-10, and PCV-13 vaccination programs from a societal perspective. We extrapolated health states to estimate the effects of the programs over the course of a lifetime of 75years. Parameters in the model were derived from a review of the literature. RESULTS: We found that PCV-7, PCV-10, and PCV-13 vaccination programs would be cost-effective compared to no vaccination. However, PCV-13 had the lowest incremental cost-effectiveness ratio ($11,464/QALY vs $16,664/QALY for PCV-10 and $18,224/QALY for PCV-7) due to a reduction in overall costs. Our sensitivity analysis revealed that the incremental cost-effectiveness ratios were most sensitive to the utility of acute otitis media, the cost of PCV-13, and the incidence of pneumonia and acute otitis media. CONCLUSIONS: The Chinese government should take steps to reduce the burden of pneumococcal diseases among young children through the inclusion of a pneumococcal conjugate vaccine in its EPI. Although all vaccinations would be cost-effective, PCV-13 would save more costs to the healthcare system and would be the preferred strategy.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Maurer KA, Chen HF, Wagner AL, et al. Cost-effectiveness analysis of pneumococcal vaccination for infants in China. Vaccine. 2016. PMID: 27810315. doi:10.1016/j.vaccine.2016.10.051

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。